Jeffrey Robert Ajer - 15 Mar 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Commercial Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
15 Mar 2023
Net transactions value
-$2,264,255
Form type
4
Filing time
17 Mar 2023, 21:16:51 UTC
Previous filing
02 Mar 2023
Next filing
17 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +10,110 +13% $0.000000 89,967 15 Mar 2023 Direct F1
transaction BMRN Common Stock Tax liability $348,416 -3,971 -4.4% $87.74 85,996 15 Mar 2023 Direct
transaction BMRN Common Stock Tax liability $1,915,839 -20,510 -24% $93.41 65,486 16 Mar 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Award $0 +23,070 $0.000000 23,070 15 Mar 2023 Common Stock 23,070 $87.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted on March 15, 2023. Price not applicable.
F2 Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter.